Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc. (PTGX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Event: Regulation FD Disclosure regarding the release of an updated corporate presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the availability of a corporate presentation and does not contain audited or unaudited financial statements.
Material Changes
No material financial changes or operational updates are detailed within the text of this 8-K filing. The document references an attached corporate presentation (Exhibit 99.1) for further details, but the content of that presentation is not included in the provided text.
Guidance, Outlook, and Risks
Management Commentary: The Company made an updated corporate presentation available to the public on January 12, 2026.
Legal Disclaimer: The information in this report and the accompanying exhibit is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filing by the Company.
Investor Verification Checklist
- Review the attached corporate presentation (Exhibit 99.1) for specific financial data, clinical trial updates, or strategic guidance not present in this summary.
- Verify the trading status of Common Stock (PTGX) on The Nasdaq Stock Market LLC.
- Confirm the Company's status as an Emerging Growth Company and any associated election regarding extended transition periods for accounting standards.
- Note that the information in this 8-K is not subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933.